Replicate Bioscience has reported promising initial clinical outcomes for its self-replicating RNA (srRNA) vaccine, RBI-4000, which is designed to combat rabies.

The trial, which is evaluating a continuous subcutaneous delivery of low-dose lenalidomide combined with dexamethasone and bortezomib, is progressing faster than expected.

Biotechnology firm ProJenX has obtained approval from the European Union to conduct a Phase 1 clinical trial, known as PRO-101, for prosetin, a groundbreaking MAP4K inhibitor.

Roivant Sciences has halted the development of its experimental drug RVT-2001 after an interim review of a Phase I/II clinical trial for myelodysplastic syndromes (MDS) revealed insufficient data to continue.

NervGen Pharma Corp. is nearing the completion of participant recruitment for its Phase 1b/2a clinical trial of NVG-291, a potential spinal cord injury treatment.

Osivax, a biopharmaceutical firm, has initiated a Phase 1 clinical trial for its sarbecovirus vaccine candidate, OVX033, in France.

This study explores the effectiveness of RP-1664, a selective oral inhibitor of polo-like kinase 4 (PLK4), targeting adult and adolescent patients with TRIM37-high solid tumors.

Theratechnologies Inc. has achieved a significant milestone in its Phase 1 clinical trial for sudocetaxel zendusortide.

Neurophth Therapeutics has successfully enrolled the final participant in its Phase I/II clinical study of Opvika® (Esonadogene Imvoparvovec), a treatment for Leber hereditary optic neuropathy (LHON) caused by the ND4 gene mutation.

Tharimmune, Inc. has successfully completed a Phase 1 clinical trial for TH104, a transmucosal buccal film containing nalmefene, which is well-tolerated with mild side effects.

May 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., together with Alvotech, have declared the launch of SIMLANDI (adalimumab-ryvk) injection within the United States.